(Z)-5-fluoro-3-((3-methyl-4-(2-morpholinoethoxy)azulen-1-yl)methylene)indolin-2-one | 1255651-40-1

• 分子结构分类: 有机化合物 - 碳氢化合物 - 不饱和烃
• 英文名称: (Z)-5-fluoro-3-((3-methyl-4-(2-morpholinoethoxy)azulen-1-yl)methylene)indolin-2-one
• 英文别名: (3Z)-5-fluoro-3-[[3-methyl-4-(2-morpholin-4-ylethoxy)azulen-1-yl]methylidene]-1H-indol-2-one
• CAS: 1255651-40-1
• 化学式: C₂₆H₂₅FN₂O₃
• 分子量: 432.495
• InChiKey: CTTXJZSRPYTLCR-JCMHNJIXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-氟吲哚-2-酮 、 3-methyl-4-(2-morpholinoethoxy)azulene-1-carbaldehyde 在 哌啶 作用下， 以 乙醇 为溶剂， 生成 (Z)-5-fluoro-3-((3-methyl-4-(2-morpholinoethoxy)azulen-1-yl)methylene)indolin-2-one
  参考文献：
  名称：

  Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors

  摘要：

  A series of azulene-based derivatives were synthesized as potent inhibitors for receptor tyrosine kinases such as FMS-like tyrosine kinase 3 (FLT-3). Systematic side chain modification of prototype 1a was carried out through SAR studies. Analogue 22 was identified from this series and found to be one of the most potent FLT-3 inhibitors, with good pharmaceutical properties, superior efficacy, and tolerability in a tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.025

文献信息

• Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors
  作者：Chih-Hung Chen、On Lee、Chung-Niang Yao、Meng-Yun Chuang、Yow-Lone Chang、May-Hua Chang、Yen-Fang Wen、Wan-Hsu Yang、Ching-Huai Ko、Nien-Tzu Chou、Mai-Wei Lin、Chin-Pen Lai、Chung-Yuan Sun、Ling-mei Wang、Yen-Chun Chen、Tzong-Hsiung Hseu、Chia-Ni Chang、Hui-Chun Hsu、Hui-Chi Lin、Yu-Li Chang、Ying-Chu Shih、Shuen-Hsiang Chou、Yi-Ling Hsu、Hsiang-Wen Tseng、Chih-Peng Liu、Chia-Mu Tu、Tsan-Lin Hu、Yuan-Jang Tsai、Ting-Shou Chen、Chih-Lung Lin、Shu-Jiau Chiou、Chung-Cheng Liu、Chrong-Shiong Hwang

  DOI：10.1016/j.bmcl.2010.08.025

  日期：2010.10

  A series of azulene-based derivatives were synthesized as potent inhibitors for receptor tyrosine kinases such as FMS-like tyrosine kinase 3 (FLT-3). Systematic side chain modification of prototype 1a was carried out through SAR studies. Analogue 22 was identified from this series and found to be one of the most potent FLT-3 inhibitors, with good pharmaceutical properties, superior efficacy, and tolerability in a tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.